EQS-News: GeoVax to Present Multi-Antigen COVID-19 Vaccine Clinical Data at September International Scientific Conferences

GEO-CM04S1 Demonstrates Promise Among Most Vulnerable Immunocompromised Patients

ATLANTA, GA - September 8, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today announced that its Chief Medical Officer and clinical collaborators will present data highlighting the cross-variant antibody and robust cellular immune responses induced by the Company’s next-generation COVID-19 vaccine (GEO-CM04S1) in immunocompromised patients with hematologic malignancies at two upcoming scientific meetings in September. Event details are as follows:

6th ESCMID Conference on Vaccines: From Development to Real-World Clinical Practice and Global Health - September 10-13, 2025; Lisbon, Portugal
Presenter: Kelly T. McKee, Jr., MD, MPH; Chief Medical Officer, GeoVax Labs, Atlanta, Georgia
Format: Poster presentation (Poster: P060)
Session Details: Friday, September 12, 2025, Lisbon, Portugal
Topic: GEO-CM04S1, a multi-antigen COVID-19 vaccine for immunocompromised individuals: clinical evaluation to date.

For more information on the conference, please visit https://www.escmid.org/congress-events/6th-escmid-conference-on-vaccines.

International Workshop on Chronic Lymphocytic Leukemia (iwCLL 2025) – September 12–15, 2025; Krakow, Poland
Presenter: Alexey V. Danilov, MD, PhD; Professor, Department of Hematology and Transplantation; City of Hope National Medical Center, Duarte, California
Format: Poster presentation (Poster: 1717)
Session Details: Monday, September 15, 2025, from 08:15 to 09:40 CEST at the ICE Auditorium Hall (S1), Levels 0 & 1
Topic: MVA-based GEO-CM04S1 vaccine results in improved cellular immune response in patients with chronic lymphocytic leukemia (CLL) compared with mRNA-based vaccine: initial results from a Phase II randomized study.

For more information on the conference, please visit https://www.iwcll.org/events/xxi-iwcll-12-15-september-2025-krakow-poland/

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com. 

Company Contact:
info@geovax.com
678-384-7220

Media Contact:
Jessica Starman
media@geovax.com